आधिकारिक वित्तीय विवरणों से राजस्व, लाभ और नकदी प्रवाह का इतिहास.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
इंटरैक्टिव चार्ट और पूर्ण वित्तीय विवरण देखें → वैल्यूएशन मॉडल (DCF) →
| आय विवरण | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| कुल राजस्व | $6.5B | $6.1B | $5.4B | $6.0B | $5.4B | $5.2B | $4.4B | $4.3B | $3.7B | $3.4B | $3.0B | $2.5B | $2.3B | $2.0B | $1.9B | $1.7B | $1.4B | $1.3B | $1.2B | $1.1B | $1.0B |
| सकल लाभ | $5.1B | $4.7B | $4.3B | $4.6B | $4.2B | $4.0B | $3.3B | $3.2B | $2.8B | $2.6B | $2.2B | $1.8B | $1.7B | $1.5B | $1.4B | $1.2B | $1.0B | $922M | $829M | $710M | $654M |
| सकल मार्जिन % | 78.0% | 78.1% | 79.5% | 77.0% | 78.3% | 76.6% | 74.9% | 73.4% | 75.2% | 74.3% | 72.8% | 72.6% | 72.8% | 73.4% | 73.3% | 72.5% | 71.7% | 69.8% | 67.0% | 65.0% | 63.0% |
| परिचालन लाभ (EBIT) | $1.8B | $1.6B | $1.4B | $1.5B | $1.7B | $1.6B | $1.3B | $1.2B | $1.1B | $1.0B | $816M | $576M | $487M | $433M | $397M | $329M | $282M | $238M | $209M | $170M | $164M |
| परिचालन मार्जिन % | 28.1% | 27.0% | 25.4% | 25.6% | 31.6% | 30.8% | 29.5% | 27.6% | 29.3% | 29.4% | 27.5% | 23.1% | 21.0% | 21.2% | 20.9% | 19.6% | 19.5% | 18.0% | 16.9% | 15.5% | 15.8% |
| शुद्ध लाभ | $1.0B | $1.1B | $4.2B | $1.4B | $1.5B | $1.5B | $823M | $1.0B | $722M | $622M | $570M | $495M | $811M | $392M | $293M | $237M | $218M | $229M | $129M | $113M | $130M |
| शुद्ध मार्जिन % | 15.4% | 17.7% | 76.8% | 23.4% | 28.3% | 28.7% | 18.8% | 24.1% | 19.4% | 18.1% | 19.2% | 19.9% | 34.9% | 19.1% | 15.4% | 14.1% | 15.1% | 17.3% | 10.4% | 10.4% | 12.6% |
| EBITDA | — | $1.4B | $1.7B | $1.5B | $2.0B | $1.9B | $1.1B | $1.3B | $872M | $1.1B | $827M | $707M | $1.2B | $590M | $453M | $345M | $327M | $297M | $227M | $214M | $240M |
| प्रति शेयर आय (EPS) | $1.74 | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $0.96 | $0.87 | $0.75 | $1.25 | $0.57 | $0.41 | $0.33 | $0.30 | $0.33 | $0.18 | $0.15 | $0.17 |
| बकाया शेयर (मिलियन) | — | 586M | 599M | 609M | 624M | 631M | 632M | 637M | 641M | 648M | 653M | 661M | 651M | 683M | 710M | 716M | 715M | 704M | 715M | 752M | 767M |
स्रोत: कंपनी की सार्वजनिक रिपोर्टें (SEC). किसी भी आँकड़े पर भरोसा करने से पहले SEC EDGAR पर उसकी पुष्टि करें.
बैलेंस शीट, नकदी प्रवाह, तिमाही आँकड़े और सभी वित्तीय अनुपात EW के इंटरैक्टिव व्यूअर में उपलब्ध हैं. /companies/us/EW
इस वेबसाइट की जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और निवेश सलाह नहीं है. कोई मूल्य लक्ष्य या सिफ़ारिश प्रकाशित नहीं की जाती.
About TickerBase · Data methodology & sources · Privacy · Terms